Covidien Device Sales Grow 10% In Q4, But Respiratory Still Faces Headwinds
This article was originally published in The Gray Sheet
Covidien's sales of laparoscopic instruments, mesh hernia repair and vessel sealing products helped drive 10% growth in the diversified firm's device business to $1.7 billion in its fiscal fourth quarter, the firm reported Nov. 17
You may also be interested in...
Covidien plans to reinvigorate its respiratory business by targeting higher-growth market segments, such as devices to combat ventilator-associated pneumonia, the company said during its Sept. 10 investor day in New York
Newly independent medical technology firm Covidien plans select acquisitions and divestitures as well as increased licensing activity to help accelerate growth following its June 29 spin-off from parent company Tyco International
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?